Forma Therapeutics signs licensing and option agreement with Novartis

Under the terms of the agreement, Forma will leverage its transformative biology and chemistry platform to develop inhibitors for an undisclosed protein-protein interaction target in the field of oncology. The agreement includes an upfront fee and potential milestones totaling over $200 million as well as royalties.

Reinhard Ambros, head of the Novartis Venture Funds, said: “Protein-protein interactions represent important target opportunities in the field of oncology drug discovery, but have been highly elusive to date. Novartis is very excited to be collaborating with Forma to access their biology and chemistry expertise and powerful discovery tools to unlock this challenging target class.”